Clinical Scorecard: Photobiomodulation for Dry AMD
At a Glance
| Category | Detail |
|---|---|
| Condition | Dry Age-Related Macular Degeneration (AMD) |
| Key Mechanisms | Uses low-intensity light to stimulate mitochondrial activity, reduce oxidative stress, and improve cellular function. |
| Target Population | Patients with early- and intermediate-stage nonexudative (dry) AMD. |
| Care Setting | Office or outpatient setting. |
Key Highlights
- PBM is FDA authorized for improving vision in dry AMD patients.
- Treatment involves 9 sessions over 3 to 5 weeks, repeated every 4 months.
- Improves mean visual acuity by approximately 1 line after 2 years.
- Requires documentation for billing, especially for Category III codes.
- Coverage for PBM may vary by payer and requires careful verification.
Guideline-Based Recommendations
Diagnosis
- Use ICD-10-CM codes from the H35.31 series for nonexudative AMD.
Management
- Perform PBM sessions as per the LIGHTSITE III trial protocol.
Monitoring & Follow-up
- Assess clinical, anatomic, and quality-of-life improvements post-treatment.
Risks
- Coverage for Category III codes may be uncertain; obtain patient waivers where necessary.
Patient & Prescribing Data
Patients with BCVA of 20/32 through 20/70 and diagnosed with dry AMD.
PBM is the first treatment shown to improve vision loss associated with dry AMD.
Clinical Best Practices
- Ensure thorough documentation of the procedure for billing.
- Investigate state-specific regulations regarding who can perform PBM.
- Obtain signed waivers from patients when coverage is uncertain.
References
- LumiThera FDA Authorization
- Photobiomodulation as a Treatment in Dry AMD
- LIGHTSITE III Study
- Aetna Category III Codes Process
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.